Substance P (SP) acting at the NK-1 neurokinin receptor has a well-documented role in the transmission and maintenance of nociceptive information. SP is found in the majority of fibers innervating the pancreas, and it is up-regulated after pancreatic inflammation. The aim of this study was to investigate the role of the NK-1 receptors in the maintenance of pancreatic nociception. Using a newly developed rat model of acute pancreatic nociception that persists for 1 week, the NK-1 receptor expression in the spinal cord and pancreas was examined using immunohistochemistry and Western blotting procedures. The effects of a specific NK-1 antagonist, CP99,994, on the behavioral manifestations of pancreatic nociception were determined. The antagonist was administered intraperitoneally and intrathecally to differentiate peripheral and central effects. Injection of CP-100,263, the inactive enantiomer of CP-99,994 was used as a control for nonspecific effects of the antagonist. Immunohistochemistry and Western blotting analysis revealed an up-regulation of the NK-1 receptor occurs in the pancreas but not at the spinal cord level. The NK-1 antagonist was able to attenuate the nociceptive behaviors in rats with pancreatitis when applied intraperitoneally with a short duration of effectiveness. Intrathecal application of the antagonist was ineffective. These results suggest the involvement of pancreatic NK-1 receptors in the maintenance of nociception during pancreatic inflammation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pbb.2004.01.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database.
Sci Rep
December 2024
Department of Pharmacy, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, 215153, China.
Background: NK-1 receptor antagonists (NK-1RAs) are proven to be successful in preventing chemotherapy-induced nausea and vomiting (CINV). The safety profile of NK-1RAs has not been systematically analyzed in the real world. This pharmacovigilance study investigated the differences in adverse events (AEs) between NK-1RAs.
View Article and Find Full Text PDFClinical benefits of adding olanzapine to 5-HT receptor antagonist, NK receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
January 2025
Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara‑Cho, Sakyo-ku, Shogoin, Kyoto, 606‑8507, Japan.
Article Synopsis
- Olanzapine is an atypical antipsychotic that helps prevent nausea and vomiting, particularly after highly emetogenic chemotherapy (HEC), but it can cause side effects like hyperglycemia and drowsiness.
- A systematic review and meta-analysis assessed the effectiveness of olanzapine combined with standard triplet antiemetic therapy compared to triplet therapy alone, focusing on outcomes like nausea control and adverse effects.
- Results showed that adding olanzapine significantly improved nausea and vomiting prevention in both acute and delayed phases with minimal adverse effects, indicating it can be beneficial for patients undergoing HEC.
Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric Oncology.
J Geriatr Oncol
October 2024
Clinic of Oncology, HFR Fribourg Hospital, Fribourg, Switzerland. Electronic address:
Corticosteroids are used frequently in oncology and many patients require short- or long-term corticosteroid therapy. General clinical guidelines and recommendations exist on the use of corticosteroids; however, evidence is lacking for recommendations on their appropriate use in older adult with cancer. Treatment of chemotherapy-induced nausea and vomiting (CINV) has dramatically improved over the last decade with 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists and neurokinin-1 (NK-1) receptor antagonists or a combination of both.
View Article and Find Full Text PDFIncidence of post-operative nausea and vomiting after endoscopic bariatric and metabolic therapy procedures and the role of neurokinin-1 receptor antagonists: a retrospective cohort study.
Surg Endosc
December 2024
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 1St Street SW, Rochester, MN, 55905, USA.
Article Synopsis
- The study investigates the incidence of postoperative nausea and vomiting (PONV) in patients who underwent endoscopic bariatric and metabolic therapies (EBMT), focusing on the impact of neurokinin-1 receptor (NK-1) antagonists on PONV rates.
- Out of 404 patients, 62.6% experienced PONV, with significant differences in rates between those who received NK-1 antagonists (35%) and those who did not (74%).
- The findings suggest that using NK-1 antagonists as part of a comprehensive approach to prevent PONV significantly lowers the likelihood of this adverse event in patients recovering from EBMT.
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
November 2024
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Article Synopsis
- - The study focuses on the effectiveness and safety of dexamethasone-sparing antiemetic therapies, particularly neurokinin-1 antagonists (NKRA), for preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic chemotherapy (HEC).
- - A systematic review of literature identified and analyzed two studies involving anthracycline-cyclophosphamide and cisplatin-based regimens; while no significant differences in vomiting prevention were found, some outcomes related to nausea showed variability.
- - The review concludes that dexamethasone-sparing antiemetic therapies can be effective in preventing CINV for HEC, particularly in patients receiving anthracycline-cyclophosphamide
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!